Hypoglycemia associated with direct‐acting anti‐hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS)-Reference-Cited by-同舟云学术

Hypoglycemia associated with direct‐acting anti‐hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS)

Published:2021-12-21 Issue: Volume: Page:
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:Clinical Endocrinology

Author:

Zhou Yu¹,Xie Wenhuo¹,Zheng Chenhua²,Liu Libin³,Chen Zhou¹,Wang Xiaolu¹

Affiliation:

1. Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy Fujian Medical University Fuzhou China

2. Experimental Teaching Center, School of Basic Medicine Fujian Medical University Fuzhou China

3. Department of Endocrinology Fujian Medical University Union Hospital Fuzhou China

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cen.14660

Reference35 articles.

1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

2. Impact of direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre‐diabetes in patients with chronic hepatitis C;Weidner P;J Gastrointestin Liver Dis,2018

3. Glucose abnormalities in Asian patients with chronic hepatitis C

4. Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review

5. Early improvement of glycaemic control after virus clearance in patients with chronic hepatitis C and severe liver fibrosis: a cohort study;Lanini S;New Microbiol,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The deleterious effects of sofosbuvir and ribavirin (antiviral drugs against hepatitis C virus) on different body systems in male albino rats regarding reproductive, hematological, biochemical, hepatic, and renal profiles and histopathological changes;Scientific Reports;2024-03-07

2. Hepatitis C: Updates in Epidemiology and for Treatment with Direct-Acting Antivirals;Global Virology IV: Viral Disease Diagnosis and Treatment Delivery in the 21st Century;2024

3. TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetes;Journal of the Formosan Medical Association;2023-03

4. Direct-acting antiviral agent use and gastrointestinal safety in patients with chronic hepatitis C: a pharmacovigilance study based on FDA Adverse Event Reporting System;International Journal of Clinical Pharmacy;2022-11-12

5. Anti-tumor Necrosis Factor-Alpha Therapy and Hypoglycemia: A Real-World Pharmacovigilance Analysis;Drug Safety;2022-07-20